Therefore, in this work, we test the effects of trastuzumab (herceptin) and fulvestrant (falsodex) as a combination in the HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474 as well as in mouse tumor xenografts. This evidence concerns the gene ERBB2 and neoplasm.